Demonstrates elevated risks of recurrent venous thromboembolism and major bleeding in cancer patients with renal disease, highlighting the need for tailored anticoagulant strategies.
Patients with active cancer and venous thromboembolism (VTE) have elevated risk of recurrent VTE (rVTE) and major bleeding (MB). The risk is even higher within those with a prior bleeding event or renal disease. There is a need to understand the risk of rVTE and MB of commonly used anticoagulants among these high-risk patients.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: